Drug intelligence / Profile preview

C5-PE38

Development stage
Preclinical
Lead developer
National Cancer Institute
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
01

Overview

**C5-PE38** is an ambiguous preclinical recombinant nanobody-PE38 immunotoxin construct name that has been independently used for at least two distinct molecules. One construct combines a canine B-cell-lymphoma-selective C5 single-domain antibody with the truncated *Pseudomonas aeruginosa* exotoxin A payload PE38 and showed cytotoxicity and tumor-growth inhibition in canine B-cell lymphoma models. A separate construct uses a C5 nanobody directed against cell-surface glucose-regulated protein 78 and was evaluated in colorectal cancer and melanoma models, where it induced endoplasmic-reticulum stress, apoptosis, immunogenic cell death, and STING-associated antitumor immune activation. These constructs should not be treated as one molecular asset merely because they share the same published construct name. ([frontiersin.org](https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1491934/full))

Other names
C5-PE38 immunotoxinC-5-PE38 immunotoxinC 5-PE38 immunotoxin
02

Targets

HSPA5 (Heat shock protein family A member 5)EEF2 (Eukaryotic elongation factor 2)

Beyond the preview

Go deeper on C5-PE38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C5-PE38.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call